The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment
Open accessAbstract
Lysosomal storage diseases are characterized by deficiencies in lysosomal enzymes, allowing accumulation of target substrate in cells and eventually causing cell death. Enzyme replacement therapy is the principal treatment for most of these diseases. However, these therapies are often complicated by immune responses to the enzymes, blocking efficacy and causing severe adverse outcomes by neutralizing product activity. It is thus crucial to understand the relationships between genetic mutations, endogenous residual enzyme proteins (cross-reactive immunologic material), development of neutralizing antibodies and their impact on clinical outcomes of lysosomal storage diseases. For patients in whom neutralizing antibodies may cause severe adverse clinical outcomes, it is paramount to develop tolerance inducing protocols to preclude, where predictable, or treat such life-threatening responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Internalization and degradation of macrophage Fc receptors bound to polyvalent immune complexes.
Mellman, I., & Plutner, H. (1984) · The Journal of cell biology · doi:10.1083/jcb.98.4.1170 · Cited by 251
Infectious tolerance and the long-term acceptance of transplanted tissue
Waldmann, H., Adams, E., Fairchild, P., & Cobbold, S. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00406.x · Cited by 177
Brooks, D. A., Kakavanos, R., & Hopwood, J. J. (2003) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2003.08.004 · Cited by 95
Vedder, A. C., Cox-Brinkman, J., Hollak, C. E. M., Linthorst, G. E., Groener, J. E. M., Helmond, M. T. J., Scheij, S., & Aerts, J. M. F. G. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.04.013 · Cited by 53
Cited by
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460
Understanding the contribution of synonymous mutations to human disease
Sauna, Z. E., & Kimchi-Sarfaty, C. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3051 · Cited by 1,022
A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease
van der Ploeg, A. T., Clemens, P. R., Corzo, D., Escolar, D. M., Florence, J., Groeneveld, G. J., Herson, S., Kishnani, P. S., Laforet, P., Lake, S. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909859 · Cited by 745
Immunogenicity of therapeutic proteins: Influence of aggregation
Ratanji, K. D., Derrick, J. P., Dearman, R. J., & Kimber, I. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2013.821564 · Cited by 589
Stimuli‐Responsive Nanocomposite Hydrogels for Biomedical Applications
Lavrador, P., Esteves, M. R., Gaspar, V. M., & Mano, J. F. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202005941 · Cited by 536
Metadata
- Authors
- Wang, J., Lozier, J., Johnson, G., Kirshner, S., Verthelyi, D., Pariser, A., Shores, E., & Rosenberg, A.
- Venue
- Nature Biotechnology
- Published
- 2008-08
- Volume
- 26
- Issue
- 8
- Pages
- 901-908
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W1984182083
- Cited by
- 170
- References
- 4
- FWCI
- 6.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. https://app.cochat.ai/papers/10.1038/nbt.1484
- The paper
- Wang, J., Lozier, J., Johnson, G., Kirshner, S., Verthelyi, D., Pariser, A., Shores, E., & Rosenberg, A. (2008). Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nature Biotechnology. https://doi.org/10.1038/nbt.1484
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.